专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060084649A9 Substituted alkyl amido piperidines 失效
标题翻译：取代的烷基酰氨基哌啶
公开(公告)号：US20060084649A9
公开(公告)日：2006-04-20
申请号：US10753057
申请日：2004-01-06
申请人： Mohammad Marzabadi , John Wetzel , Chien-An Chen , Yu Jiang , Kai Lu
发明人： Mohammad Marzabadi , John Wetzel , Chien-An Chen , Yu Jiang , Kai Lu
IPC分类号： A61K31/53 , A61K31/506 , A61K31/497 , C07D43/04
CPC分类号： C07D211/26 , C07D211/28 , C07D211/90 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

2. 发明申请

US20080045524A1 Selective NPY (Y5) antagonists 审中-公开
标题翻译：选择性NPY（Y5）拮抗剂
公开(公告)号：US20080045524A1
公开(公告)日：2008-02-21
申请号：US11716925
申请日：2007-03-12
申请人： Mohammad Marzabadi , Wai Wong , Stewart Noble , Mahesh Desai
发明人： Mohammad Marzabadi , Wai Wong , Stewart Noble , Mahesh Desai
IPC分类号： A61K31/53 , A61K31/426 , A61K31/5377 , C07D251/54 , C07D413/12 , C07D417/04 , C07D413/14 , C07D277/38 , A61P3/00 , A61K31/4436
CPC分类号： C07D401/12 , C07D251/70 , C07D277/28 , C07D277/42 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D417/14 , C07D513/04
摘要： This invention is directed to triazine derivatives, bicyclic compounds and tricyclic compounds which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.
摘要翻译：本发明涉及作为NPY（Y5）受体的选择性拮抗剂的三嗪衍生物，双环化合物和三环化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物和药学上可接受的载体组合而制备的药物组合物。本发明提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供了本发明化合物在制备用于治疗异常的药物组合物中的用途，其中通过降低人Y5受体的活性来减轻异常。

3. 发明申请

US20060173027A1 Spirocvclic piperidines as mch1 antagonists and uses thereof 失效
标题翻译：作为mch1拮抗剂的西吡唑哌啶及其用途
公开(公告)号：US20060173027A1
公开(公告)日：2006-08-03
申请号：US10518939
申请日：2003-07-03
申请人： Mohammad Marzabadi , Yu Jiang , Kai Lu , Chien-An Chen , John De Leon , John Wetzel , Kim Andersen
发明人： Mohammad Marzabadi , Yu Jiang , Kai Lu , Chien-An Chen , John De Leon , John Wetzel , Kim Andersen
IPC分类号： A61K31/4747
CPC分类号： C07D221/20 , C07D401/06 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D491/10
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用有效治疗受试者抑郁症和/或焦虑的量的本发明化合物。本发明还提供了治疗患有尿失禁的受试者的方法。

4. 发明申请

US20050154022A1 4-aryl piperidines 审中-公开
标题翻译： 4-芳基哌啶
公开(公告)号：US20050154022A1
公开(公告)日：2005-07-14
申请号：US11034611
申请日：2005-01-13
申请人： Mohammad Marzabadi , John Wetzel , Chien-An Chen , John DeLeon , Yu Jiang , Kai Lu
发明人： Mohammad Marzabadi , John Wetzel , Chien-An Chen , John DeLeon , Yu Jiang , Kai Lu
IPC分类号： C07D211/26 , C07D401/12 , A61K31/4545 , C07D41/14
CPC分类号： C07D401/12 , C07D211/26
摘要： This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的4-芳基哌啶和相关的杂环化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

5. 发明申请

US20060079522A1 Amino substituted aryloxybenzylpiperidine derivatives 审中-公开
标题翻译：氨基取代的芳氧基苄基哌啶衍生物
公开(公告)号：US20060079522A1
公开(公告)日：2006-04-13
申请号：US10962099
申请日：2004-10-08
申请人： Mohammad Marzabadi , Chien-An Chen , Yu Jiang , Kai Lu , Kim Andersen
发明人： Mohammad Marzabadi , Chien-An Chen , Yu Jiang , Kai Lu , Kim Andersen
IPC分类号： A61K31/5377 , A61K31/496 , A61K31/4545 , C07D403/14 , C07D413/14
CPC分类号： C07D211/26 , C07D401/12 , C07D403/12
摘要： This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention.
摘要翻译：本发明涉及作为MCH1受体的配体的氨基取代的芳氧基苄基哌啶衍生物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的本发明化合物。本发明还提供了治疗患有肥胖症的受试者的方法，其包括给予受试者一定量的本发明化合物。

6. 发明申请

US20050154020A1 4-Aryl piperidines 审中-公开
标题翻译： 4-芳基哌啶
公开(公告)号：US20050154020A1
公开(公告)日：2005-07-14
申请号：US10757962
申请日：2004-01-14
申请人： Mohammad Marzabadi , John Wetzel , Chien-An Chen , John Deleon , Yu Jiang , Kai Lu
发明人： Mohammad Marzabadi , John Wetzel , Chien-An Chen , John Deleon , Yu Jiang , Kai Lu
IPC分类号： C07D211/26 , A61K31/4545 , C07D41/14
CPC分类号： C07D211/26
摘要： This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的4-芳基哌啶和相关的杂环化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

7. 发明申请

US20070043080A1 Substituted anilinic piperidines as MCH selective antagonists 审中-公开
标题翻译：取代的苯胺哌啶类作为MCH选择性拮抗剂
公开(公告)号：US20070043080A1
公开(公告)日：2007-02-22
申请号：US11214968
申请日：2005-08-30
申请人： Mohammad Marzabadi , John Wetzel , John DeLeon , Yu Jiang , Chien-An Chen , Kai Lu
发明人： Mohammad Marzabadi , John Wetzel , John DeLeon , Yu Jiang , Chien-An Chen , Kai Lu
IPC分类号： A61K31/445 , C07D211/26
CPC分类号： C07D401/04 , C07D211/26 , C07D211/28 , C07D211/90 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/10 , C07D471/04 , C07D495/04
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。

8. 发明申请

US20060079524A1 Amino substituted aryloxybenzylpiperidine derivatives 失效
标题翻译：氨基取代的芳氧基苄基哌啶衍生物
公开(公告)号：US20060079524A1
公开(公告)日：2006-04-13
申请号：US11230849
申请日：2005-09-20
申请人： Mohammad Marzabadi , Chien-An Chen , Yu Jiang , Kai Lu , Kim Andersen
发明人： Mohammad Marzabadi , Chien-An Chen , Yu Jiang , Kai Lu , Kim Andersen
IPC分类号： A61K31/5377 , A61K31/4545 , A61K31/496 , C07D413/14 , C07D403/14
CPC分类号： C07D211/26 , C07D211/34 , C07D401/12 , C07D403/12
摘要： This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.
摘要翻译：本发明涉及作为MCH1受体的配体的氨基取代的芳氧基苄基哌啶衍生物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。本发明还提供了治疗患有肥胖症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。

9. 发明申请

US20050245743A1 Secondary amino anilinic piperidines as mch1 antagonists and uses thereof 失效
标题翻译：仲氨基苯胺哌啶类作为mch1拮抗剂及其应用
公开(公告)号：US20050245743A1
公开(公告)日：2005-11-03
申请号：US10518675
申请日：2003-07-03
申请人： Mohammad Marzabadi , Jiang Yu , Kai Lu , Chien-An Chen , John De Leon , John Wetzel
发明人： Mohammad Marzabadi , Jiang Yu , Kai Lu , Chien-An Chen , John De Leon , John Wetzel
IPC分类号： A61K31/44 , A61K31/451 , A61K31/4545 , A61K31/506 , A61P3/04 , A61P13/02 , A61P25/22 , A61P25/24 , A61P43/00 , C07D211/26 , C07D211/70 , C07D401/12 , C07D211/68 , C07D41/02 , C07D43/02
CPC分类号： C07D211/26 , C07D401/12
摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compounds of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.
摘要翻译：本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物与药学上可接受的载体组合。本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用有效治疗受试者抑郁症和/或焦虑的量的本发明化合物。本发明还提供了治疗患有尿失禁的受试者的方法。

10. 发明申请

US20050176709A1 Selective NPY (Y5) antagonists 失效
标题翻译：选择性NPY（Y5）拮抗剂
公开(公告)号：US20050176709A1
公开(公告)日：2005-08-11
申请号：US11099960
申请日：2005-04-06
申请人： Mohammad Marzabadi , Wai Wong , Stewart Noble , Manesh Desai
发明人： Mohammad Marzabadi , Wai Wong , Stewart Noble , Manesh Desai
IPC分类号： A61K31/427 , A61K31/429 , A61K31/4427 , A61K31/4439 , A61K31/53 , A61K31/5377 , A61P3/00 , A61P3/04 , A61P7/04 , A61P9/04 , A61P9/10 , A61P9/12 , A61P15/08 , A61P25/08 , A61P25/20 , A61P25/24 , A61P43/00 , C07D251/70 , C07D277/28 , C07D401/04 , C07D401/12 , C07D403/12 , C07D409/12 , C07D413/04 , C07D413/12 , C07D417/04 , C07D417/12 , C07D417/14 , C07D513/04 , C07D519/00 , A61K31/43 , C07D498/02
CPC分类号： C07D401/12 , C07D251/70 , C07D277/28 , C07D277/42 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D417/14 , C07D513/04
摘要： This invention is directed to triazine derivatives, bicyclic compounds and tricyclic compounds which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.
摘要翻译：本发明涉及作为NPY（Y5）受体的选择性拮抗剂的三嗪衍生物，双环化合物和三环化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物和药学上可接受的载体组合而制备的药物组合物。本发明提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供了本发明化合物在制备用于治疗异常的药物组合物中的用途，其中通过降低人Y5受体的活性来减轻异常。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式